187 related articles for article (PubMed ID: 19461936)
1. Modulation of NKT cells and Th1/Th2 imbalance after alpha-GalCer treatment in progressive load-trained rats.
Ru W; Peijie C
Int J Biol Sci; 2009 May; 5(4):338-43. PubMed ID: 19461936
[TBL] [Abstract][Full Text] [Related]
2. Activation of natural killer T cells by α-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis.
Yoshiga Y; Goto D; Segawa S; Horikoshi M; Hayashi T; Matsumoto I; Ito S; Taniguchi M; Sumida T
Clin Exp Immunol; 2011 May; 164(2):236-47. PubMed ID: 21391989
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.
Hayakawa Y; Takeda K; Yagita H; Van Kaer L; Saiki I; Okumura K
J Immunol; 2001 May; 166(10):6012-8. PubMed ID: 11342617
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
5. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
[TBL] [Abstract][Full Text] [Related]
6. An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes.
Ly D; Tohn R; Rubin B; Blumenfeld H; Besra GS; Veerapen N; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2010 May; 160(2):185-98. PubMed ID: 20015094
[TBL] [Abstract][Full Text] [Related]
7. The role of invariant NKT cells in liver transplant tolerance in rats.
Liu Y; Luan X; Li J; He Y; Li M
Transplant Proc; 2012 May; 44(4):1041-4. PubMed ID: 22564620
[TBL] [Abstract][Full Text] [Related]
8. Natural killer T cell ligand alpha-galactosylceramide protects against gut ischemia reperfusion-induced organ injury in mice.
Zhang J; Bi J; Ren Y; Du Z; Li T; Li Q; Ke M; Dong J; Lv Y; Wu R
Cytokine; 2018 Nov; 111():237-245. PubMed ID: 30195979
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer T Cells Are Numerically and Functionally Deficient in Patients with Trauma.
Jo YG; Kim JC; Jin HM; Cho YN; Kee SJ; Park YW
J Innate Immun; 2020; 12(4):344-354. PubMed ID: 32450553
[TBL] [Abstract][Full Text] [Related]
10. Natural killer T cells from interleukin-4-deficient mice are defective in early interferon-gamma production in response to alpha-galactosylceramide.
Togashi Y; Chamoto K; Wakita D; Tsutsumi N; Iwakura Y; Matsubara N; Kitamura H; Nishimura T
Cancer Sci; 2007 May; 98(5):721-5. PubMed ID: 17359285
[TBL] [Abstract][Full Text] [Related]
11. Schistosoma mansoni and alpha-galactosylceramide: prophylactic effect of Th1 Immune suppression in a mouse model of Graves' hyperthyroidism.
Nagayama Y; Watanabe K; Niwa M; McLachlan SM; Rapoport B
J Immunol; 2004 Aug; 173(3):2167-73. PubMed ID: 15265954
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.
Tohn R; Blumenfeld H; Haeryfar SM; Veerapen N; Besra GS; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2011 Apr; 164(1):26-41. PubMed ID: 21361909
[TBL] [Abstract][Full Text] [Related]
13. A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner.
Coppieters K; Van Beneden K; Jacques P; Dewint P; Vervloet A; Vander Cruyssen B; Van Calenbergh S; Chen G; Franck RW; Verbruggen G; Deforce D; Matthys P; Tsuji M; Rottiers P; Elewaut D
J Immunol; 2007 Aug; 179(4):2300-9. PubMed ID: 17675491
[TBL] [Abstract][Full Text] [Related]
14. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
[TBL] [Abstract][Full Text] [Related]
15. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
16. Preactivation of NKT cells with alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor.
Cao Z; Yuan Y; Jeyabalan G; Du Q; Tsung A; Geller DA; Billiar TR
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G249-58. PubMed ID: 19556359
[TBL] [Abstract][Full Text] [Related]
17. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
[TBL] [Abstract][Full Text] [Related]
18. IL-18 time-dependently modulates Th1/Th2 cytokine production by ligand-activated NKT cells.
Uchida T; Kinoshita M; Fukasawa M; Habu Y; Shinomiya N; Seki S
Eur J Immunol; 2007 Apr; 37(4):966-77. PubMed ID: 17330820
[TBL] [Abstract][Full Text] [Related]
19. Essential role of LFA-1 in activating Th2-like responses by alpha-galactosylceramide-activated NKT cells.
Matsumoto G; Kubota E; Omi Y; Lee U; Penninger JM
J Immunol; 2004 Oct; 173(8):4976-84. PubMed ID: 15470040
[TBL] [Abstract][Full Text] [Related]
20. Natural killer T cell activation increases iNOS
Paul S; Chhatar S; Mishra A; Lal G
J Immunother Cancer; 2019 Aug; 7(1):208. PubMed ID: 31387637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
